Sagimet reports 52-week Phase 3 extension data showing 56.7% IGA success for denifanstat

Sagimet Biosciences said 52-week results from Ascletis’ Phase 3 open-label extension of denifanstat in moderate to severe acne showed 56.7% IGA success, with sustained improvements and no adverse event-related permanent discontinuations reported.